– Brings over 30 years of senior financial experience in the biopharmaceutical, MedTech, investment banking and accounting sectors –
Uppsala, Sweden, April 27, 2021 – The Nomination Committee of Oasmia Pharmaceutical AB (“Oasmia”), an innovation-focused specialty pharmaceutical company, proposes Andreas Buscaglia to be elected as new member of the Board of Directors at the Annual General Meeting on 27 May 2021.
The Nomination Committee is in addition proposing re-election of Anders Härfstrand, Hege Hellström, Birgit Stattin Norinder and Peter Zonabend. The Nomination Committee proposes Anders Härfstrand to be re-elected as Chairman of the Board of Directors.
Mr Buscaglia brings extensive financial experience from over 30 years working in senior roles in the biopharmaceutical, MedTech, investment banking and accounting sectors. He is currently the Chief Financial Officer (CFO) of Medicines for Malaria Venture (MMV), a leading product development partnership in the field of antimalarial drug research and development
Anders Härfstrand, Chairman of the Board of Directors of Oasmia and member of the Nomination Committee, commented: “Andrea has had an impressive career and we are excited to welcome him to the Oasmia Board. His extensive experience and network of business and financial contacts will be incredibly useful as we embark on the next stage in our transformation and implement long-term growth plans.”
Commenting on his appointment to Oasmia’s Board Andrea Buscaglia added: “It is an exciting time to be joining Oasmia. I look forward to working with Anders and the Oasmia Board to share my expertise and contacts and help support business growth.”
Prior to joining MMV in 2012 Mr Buscaglia was CFO of medical device and biopharmaceutical companies Endosense (now Abbott Laboratories) from 2009 until 2012 and Nitec Pharma (now Horizon Therapeutics) from 2007 until 2009, raising several rounds of venture capital funding and playing a pivotal role in M&A activity.
Earlier in his career, from 2000 until 2007, Mr Buscaglia was Vice President Corporate Development at Serono (now Merck KGaA), Europe’s largest biotech company at the time, where he played a pivotal role in the $2 billion equity offering and New York Stock Exchange listing, as well as in investor relations, M&A, and licensing activities.
Mr Buscaglia began his career as an auditor with Arthur Anderson & Co. in Milan and then worked for a total of eight years with three investment banks, namely S.G. Warburg & Co. Ltd. (now UBS), Deutsche Bank and Salomon Smith Barney (Citigroup), with a focus on Equity Capital Markets (IPOs, secondary offerings, public tender offers) and M&A transactions in Italy.
Mr Buscaglia holds a Degree in Business Administration from the Bocconi University in Milan, Italy and a Diploma in Accountancy from the University of Genoa, Italy.
The members of the Nomination Committee are Per Arwidsson (appointed by Arwidsro Investment AB, Chairman of the Nomination Committee), Håkan Lagerberg (appointed by Mastan AB) and Anders Härfstrand (Chairman of the Board of Directors of Oasmia).
Information about the proposed Board members, the Nomination Committee’s complete proposal and the Nomination Committee’s statement will be made available on Oasmia’s website, www.vivesto.com, in connection with the publication of the notice of the Annual General Meeting.
For More Information:
Oasmia Pharmaceutical AB
Francois Martelet, Chief Executive Officer
Phone: +46 18-50 54 40
E-mail: IR@oasmia.com
Consilium Strategic Communications (For Oasmia)
Jonathan Birt, Chris Welsh, Ashley Tapp
Phone: +44 (0)20 3709 5700
E-mail: oasmia@consilium-comms.com
About Oasmia Pharmaceutical AB
Oasmia is a specialty pharma company dedicated to improving the lives of patients by enhancing the intravenous delivery of established and novel drugs in significant diseases, including cancer. Product development is based on Oasmia’s proprietary drug delivery platforms which can be applied to medicines used in many therapeutic areas, to develop water soluble formulations of drugs that currently require chemical solubilizers for dissolution. The first product approved using this technology is Apealea® (paclitaxel micellar). Apealea has received market authorization in the European Union and several other territories for the treatment of first relapse in platinum-sensitive ovarian cancer, in combination with carboplatin. The Company is making Apealea accessible to patients through its partnership with Elevar Therapeutics, together with its existing commercial operations in the Nordic region. Oasmia’s shares are traded on the Nasdaq Stockholm stock exchange (ticker: OASM). To find out more about Oasmia please visit www.vivesto.com.